BridgeMD
CANDISHORT : A randomized study of a short duration therapy for candidemia
EU CTIS ID: 2024-514244-81-00
What this study is testing
To demonstrate that, in uncomplicated candidemia, a duration of treatment of 7 days after the first negative blood culture is non-inferior to a duration of 14 days after the first negative blood culture for all-cause mortality (ACM) at Day 28 (+/- 2 days).
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult (Age ≥ 18 years old) with a predicted life expectancy > 4 weeks
- With a positive Candida sp. blood culture allowing the diagnosis of candidemia
- Results of the 1st positive blood culture less than 72 hours at the time of inclusion
- If the patient is in aplasia (defined by neutrophil count below 500/mm3), predictive duration of aplasia must be less than 7 days
- Individual affiliated to a social security regimen
- Written informed consent from the patient or his/her relatives
You likely can't join if
- Presence of an indwelling vascular catheter or device that cannot be removed or an abscess that cannot be drained and is likely to be the source of candidemia or the presence of secondary sites of candidemia requiring prolonged treatment
- Candida strain resistant to the antifungal used
- Hypersensitivity or previous severe adverse drug reaction to the antifungal treatments
- Patient under legal guardianship
- Pregnancy, breastfeeding
- Woman with childbearing age who has not used or does not plan to use acceptable birth control measures
See the full eligibility criteria
- Adult (Age ≥ 18 years old) with a predicted life expectancy > 4 weeks
- With a positive Candida sp. blood culture allowing the diagnosis of candidemia
- Results of the 1st positive blood culture less than 72 hours at the time of inclusion
- If the patient is in aplasia (defined by neutrophil count below 500/mm3), predictive duration of aplasia must be less than 7 days
- Individual affiliated to a social security regimen
- Written informed consent from the patient or his/her relatives
- Presence of an indwelling vascular catheter or device that cannot be removed or an abscess that cannot be drained and is likely to be the source of candidemia or the presence of secondary sites of candidemia requiring prolonged treatment
- Candida strain resistant to the antifungal used
- Hypersensitivity or previous severe adverse drug reaction to the antifungal treatments
- Patient under legal guardianship
- Pregnancy, breastfeeding
- Woman with childbearing age who has not used or does not plan to use acceptable birth control measures
- Unwilling, in the judgment of the investigator, to comply with the protocol
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.